leisure time -WSS

leisure time

author：fashion 2025-10-04 04:01:14 - browse：75

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： South Korea throws huge K

WSS

Eliminate the waiting period for sterilization covered by Medicaid

NIH trials fail to test meaningful long Covid therapies, experts say

Scientists boost immune system in aging mice by making it youthful

Primary care physicians play key roles in Alzheimer's management

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

hotspot

leisure time

entertainment

Supreme Court strikes down use of affirmative action

Vertex Pharmaceuticals may move headquarters in Boston

Activists slam private health insurers over coverage restrictions

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

As demand for Covid shots wanes, Moderna seeks its next success

Steward Health Care has deal to sell doctor network to UnitedHealth

Psychedelics group wrestles with new pharma identity

Emergent cuts jobs, executive role in business shake

United colonoscopy coverage change 'may cost lives,' doctors say

Why failed clinical trials don’t always spell doom for a new drug

focus

What to know about Virgin Galactic's 1st mission taking paying customers to space

American woman, child freed after being kidnapped in Haiti last month

Drastic changes should bring profitability, startup health insurers say

Study says nonprofit hospitals fall short in charity care spending

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

There's no autism epidemic. It's an autism diagnosis epidemic

leisure time

hotspot

leisure time

leisure time